A comparative study of matrix metalloproteinase and aggrecanase mediated release of latent cytokines at arthritic joints
- 1 September 2014
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (9) , 1728-1736
Abstract
Background Latent cytokines are engineered by fusing the latency associated peptide (LAP) derived from transforming growth factor-β (TGF-β) with the therapeutic cytokine, in this case interferon-β (IFN-β), via an inflammation-specific matrix metalloproteinase (MMP) cleavage site. Objectives To demonstrate latency and specific delivery in vivo and to compare therapeutic efficacy of aggrecanase-mediated release of latent IFN-β in arthritic joints to the original MMP-specific release. Methods Recombinant fusion proteins with MMP, aggrecanase or devoid of cleavage site were expressed in CHO cells, purified and characterised in vitro by Western blotting and anti-viral protection assays. Therapeutic efficacy and half-life were assessed in vivo using the mouse collagen-induced arthritis model (CIA) of rheumatoid arthritis and a model of acute paw inflammation, respectively. Transgenic mice with an IFN-regulated luciferase gene were used to assess latency in vivo and targeted delivery to sites of disease. Results Efficient localised delivery of IFN-β to inflamed paws, with low levels of systemic delivery, was demonstrated in transgenic mice using latent IFN-β. Engineering of latent IFN-β with an aggrecanase-sensitive cleavage site resulted in efficient cleavage by ADAMTS-4, ADAMTS-5 and synovial fluid from arthritic patients, with an extended half-life similar to the MMP-specific molecule and greater therapeutic efficacy in the CIA model. Conclusions Latent cytokines require cleavage in vivo for therapeutic efficacy, and they are delivered in a dose dependent fashion only to arthritic joints. The aggrecanase-specific cleavage site is a viable alternative to the MMP cleavage site for the targeting of latent cytokines to arthritic joints.Keywords
This publication has 21 references indexed in Scilit:
- Increased disulphide dimer formation of latent associated peptide fusions of TGF-β by addition of l-cystineJournal of Biotechnology, 2012
- Molecular engineering of short half-life small peptides (VIP, αMSH and γ3MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeuticsAnnals of the Rheumatic Diseases, 2012
- Latent TGF-β structure and activationNature, 2011
- Temporal and Spatial Resolution of Type I and III Interferon ResponsesIn VivoJournal of Virology, 2010
- Progress in matrix metalloproteinase researchMolecular Aspects of Medicine, 2008
- Matrix‐degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomasInternational Journal of Cancer, 2005
- Targeting cytokines to inflammation sitesNature Biotechnology, 2003
- Inhibition of established collagen-induced arthritis with a tumour necrosis factor-α inhibitor expressed from a self-contained doxycycline regulated plasmidArthritis Research & Therapy, 2003
- TGF-β: from latent to activeMicrobes and Infection, 1999
- Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.Proceedings of the National Academy of Sciences, 1992